Neurones AI Stock Analysis
Want to see FR:NRO full AI Analyst Report?
Neurones (NRO) AI Stock Analysis
Neurones
(Paris:NRO)
Neurones earns a strong overall score, primarily driven by its exceptional financial fundamentals, minimal debt, and consistent profitability. Its valuation is compelling, supported by a healthy dividend yield and a reasonable earnings multiple. While the long-term technical trend is highly bullish, investors should be aware of overbought oscillators that indicate potential short-term price consolidation.
Neurones (NRO) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 967.42M
- Dividend Yield
- 3.53%
- Average Volume (3M)
- 6,433
- Price to Earnings (P/E)
- 17.4
- Beta (1Y)
- 0.41
- Revenue Growth
- 6.68%
- EPS Growth
- 9.16%
- Country
- France
- Employees
- 7,329
- Sector
- General
- Sector Strength
- 55
- Industry
- Information Technology Services
Neurones Business Overview & Revenue Model
Company Description
Neurones S.A., an information technology (IT) services provider founded in 1984 and headquartered in Nanterre, France, operates with a global reach. The company delivers a broad spectrum of services encompassing infrastructure, application developmen...
How the Company Makes Money
Neurones makes money primarily by selling professional services to business and public-sector clients under consulting and IT services engagements. Revenue is mainly generated from (1) time-and-materials consulting and engineering assignments billed...
Neurones Financial Statement Overview
Summary
Neurones presents a stellar financial profile characterized by consistent top-line growth, an unleveraged balance sheet with a low debt-to-equity ratio of 0.09, and robust free cash flow generation. The score is marginally held back by a slight recent contraction in EBITDA margins.
Income Statement
82Very PositiveBalance Sheet
92Very PositiveCash Flow
86Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 887.74M | 857.20M | 810.40M | 741.17M | 665.38M | 579.88M |
| Gross Profit | 504.95M | 90.04M | 388.76M | 346.76M | 81.64M | 69.73M |
| EBITDA | 96.35M | 90.32M | 95.56M | 96.63M | 88.72M | 76.33M |
| Net Income | 55.29M | 52.07M | 52.50M | 49.41M | 44.24M | 37.71M |
Balance Sheet | ||||||
| Total Assets | 730.02M | 749.03M | 725.69M | 674.25M | 616.22M | 567.82M |
| Cash, Cash Equivalents and Short-Term Investments | 301.88M | 340.78M | 326.49M | 297.76M | 272.06M | 265.17M |
| Total Debt | 41.30M | 36.96M | 42.02M | 43.98M | 35.57M | 35.32M |
| Total Liabilities | 296.68M | 284.16M | 289.52M | 266.34M | 240.63M | 214.90M |
| Stockholders Equity | 376.16M | 399.98M | 378.10M | 354.39M | 330.58M | 311.56M |
Cash Flow | ||||||
| Free Cash Flow | 88.59M | 70.33M | 72.34M | 54.09M | 44.33M | 58.10M |
| Operating Cash Flow | 100.76M | 80.77M | 84.38M | 72.08M | 54.94M | 64.68M |
| Investing Cash Flow | -23.85M | -21.16M | -19.69M | -21.57M | -12.26M | -10.62M |
| Financing Cash Flow | -67.63M | -45.11M | -34.48M | -27.06M | -36.08M | -55.42M |
Neurones Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:NRO, the sentiment is Positive. The current price of 39.70 is above the 20-day moving average (MA) of 38.90, above the 50-day MA of 37.32, and above the 200-day MA of 36.04, indicating a bullish trend. The MACD of 1.08 indicates Negative momentum. The RSI at 57.10 is Neutral, neither overbought nor oversold. The STOCH value of 65.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:NRO.
Neurones Peers Comparison
Overall Rating
FR:NRO84Outperform
FR:WAVE83Outperform
FR:SOP72Outperform
FR:CAP67Neutral
FR:ATE66Neutral
FR:ATO39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | EUR 946.55M | 17.41 | 14.25% | 3.53% | 6.68% | 9.16% | |
| 83Outperform | EUR 851.85M | 10.31 | 12.19% | 1.45% | 1.13% | 8.32% | |
| 72Outperform | EUR 3.65B | 12.26 | 14.45% | 2.78% | 1.62% | 12.95% | |
| 67Neutral | EUR 20.45B | 14.80 | 11.82% | 2.82% | 6.23% | -11.48% | |
| 66Neutral | EUR 2.94B | 20.73 | 6.19% | 1.79% | 0.11% | -6.28% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 39Underperform | EUR 443.04M | -0.37 | 117.34% | ― | -14.39% | -173.10% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:NRO | Neurones | 39.70 | -1.20 | -2.93% | |
| FR:ATE | ALTEN | 83.95 | 21.23 | 33.84% | |
| FR:ATO | Atos SE | 22.24 | -20.36 | -47.79% | |
| FR:CAP | Capgemini | 120.65 | -2.44 | -1.98% | |
| FR:SOP | Sopra Steria | 190.70 | 66.28 | 53.28% | |
| FR:WAVE | Wavestone SA | 34.45 | -12.93 | -27.29% |
Neurones Corporate Events
NEURONES Reports 7.1% Organic Growth in Third Quarter
NEURONES is a French management consulting and digital services company that helps major organizations deliver digital projects, transform IT infrastructures and accelerate AI adoption. Its activities include data and AI, digital projects, IT service...
Neurones Releases Half-Year Financial Report for First Half of 2026
Neurones has published its half-year financial report for the period ending 30 June 2026, providing stakeholders with an overview of its activity, consolidated financial statements and related certifications.The release highlights that the report inc...
Neurones Delivers Strong First-Half 2026 Growth and Reaffirms Margin Guidance
Neurones reported first-half 2026 revenues of €454.8 million, up 7.2% year-on-year, driven largely by 6.9% organic growth and confirming its momentum in digital consulting and IT services. Operating profit rose 19.9% to represent 8.7% of revenue, whi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
